业绩稳定增长，外延并购持续赋能

Investment Rating - The investment rating for the company is maintained as "Outperform" [6][17]. Core Insights - The company reported a revenue of 403 million yuan for 2023, representing a year-on-year growth of 6.55%, while the net profit attributable to shareholders decreased by 7.48% to 86 million yuan [17]. - In Q4 2023, the company achieved a revenue of 120 million yuan, a year-on-year increase of 6.79%, and a net profit of 31 million yuan, reflecting a growth of 16.23% compared to the previous year [17]. - The company plans to acquire 51% of Shanghai Yuanye Biotechnology for approximately 181 million yuan, aiming to enhance its product line and competitive edge in the market [18]. Financial Data Summary - Total revenue for 2022 was 378 million yuan, with a projected increase to 445 million yuan in 2024, reflecting a growth rate of 10.5% [20]. - The net profit for 2022 was 93 million yuan, expected to rise to 123 million yuan in 2024, indicating a growth rate of 42.8% [20]. - The earnings per share (EPS) for 2022 was 0.65 yuan, projected to increase to 0.62 yuan in 2024 [20].